Acute/subacute severe cerebral venous thrombosis
Conditions
Interventions
Standard anticoagulation group:Low molecular weight heparin followed by bridging to warfarin or other oral anticoagulants.
Corticosteroid?adjuvant plus standard anticoagulation group:Methylprednisolone pulse and sequential tapering therapy.
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis of cerebral venous thrombosis (CVT) is established by an experienced neurologist based on comprehensive assessment of clinical presentation, medical history, physical examination, and ancillary examination results; among which, imaging confirmation must be obtained by conventional magnetic resonance imaging (MRI) or magnetic resonance black-blood thrombus imaging (MRBTI) sequences; 2. Patients with severe CVT (Note: Severity is defined as meeting any one of the following criteria: presence of complications including venous cerebral infarction, intracerebral hemorrhage, subarachnoid hemorrhage, epileptic seizures, or impaired consciousness); 3. Currently in the acute/subacute phase (Note: Acute/subacute phase is defined as time from symptom onset to admission <=15 days, OR time from symptom worsening to admission =15 days, AND imaging shows thrombus signal characteristics consistent with acute/subacute stage on T1/T2-weighted sequences, contrast-enhanced MRI, or MRBTI); 4. Aged 14–80 years; 5. Both sexes; 6. Provide written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Age <14 years or foreign patients; 2. Pregnant women or postpartum women within 42 days after delivery; 3. Presence of any severe systemic disease with poor prognosis within 1 year, such as acute cerebral infarction, traumatic brain injury, cancer, unstable angina, uncontrolled asthma, etc; 4. Diagnosis of immune-related diseases (e.g., Behçet's disease, systemic lupus erythematosus, etc.) based on medical history and admission examination results; 5. Active progressive tuberculosis; 6. Patients with severe diseases of the circulatory, respiratory, urinary, digestive, or hematopoietic systems; 7. Absolute contraindications to corticosteroid use, such as uncontrolled infection, severe diabetes mellitus, etc; 8. Pre-onset modified Rankin Scale (mRS) score =3; 9. Cerebral herniation with refusal of decompressive craniectomy, or no recovery of pupillary light reflex after decompressive craniectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of good functional outcome (defined as a modified Rankin Scale [mRS] score of 0–2).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events related to corticosteroid use;National Institutes of Health Stroke Scale (NIHSS) score;Recurrence of cerebral venous thrombosis;Dynamic changes in serum and cerebrospinal fluid proteomics;All-cause mortality rate;A modified Rankin Scale (mRS) score; | — |
Countries
China
Contacts
Public ContactDuan Jiangang
Xuanwu Hospital, Capital Medical University
Outcome results
None listed